This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koudstaal, P. J. Articles by Patrono, C. Search for Related Content PubMed PubMed Citation Articles by Koudstaal, P. J. Articles by Patrono, C.

Stroke, Vol 24, 219-223, Copyright © 1993 by American Heart Association

ARTICLES

Increased thromboxane biosynthesis in patients with acute cerebral ischemia

PJ Koudstaal, G Ciabattoni, J van Gijn, HK Nieuwenhuis, PG de Groot, JJ Sixma and C Patrono
Department of Neurology, University Hospital Rotterdam, The Netherlands.

BACKGROUND AND PURPOSE: Clinical and experimental studies suggest that platelets have a major role in the pathogenesis of cerebral ischemia. However, ex vivo both platelet aggregation studies and measurements of platelet-derived products in patients with cerebral ischemia have shown inconsistent results. The present study was designed to resolve this inconsistency. METHODS: We have measured the urinary excretion of a thromboxane metabolite, 11-dehydro-thromboxane B2, by a previously validated radioimmunoassay technique in 51 patients with acute cerebral ischemia who had experienced either a transient ischemic attack (14 patients) or an ischemic stroke (37 patients) and in 20 control patients with nonvascular neurological disorders. The median time between the onset of symptoms and urine sampling was 24 hours (range, from 2 hours to 8 days). RESULTS: The excretion rate of immunoreactive 11-dehydro-thromboxane B2 ranged between 39 and 478 pmol/mmol creatinine in patients with a transient ischemic attack and between 23 and 5,916 pmol/mmol creatinine in stroke patients, with 29% (p = 0.18) and 51% (p = 0.004) of the urine samples, respectively, exceeding the upper limit of the control samples (251 pmol/mmol creatinine [mean +/- 2 SD]) (p = 0.01). In stroke patients, metabolite excretion was not related to the type (cortical or "lacunar") or site of cerebral infarction. Low-dose aspirin (50 mg per day for 7 days) reduced the urinary excretion by approximately 85% in 11 consecutive stroke patients. CONCLUSIONS: We conclude that 1) episodes of enhanced thromboxane biosynthesis are detected infrequently in patients with a transient ischemic attack, 2) aspirin-suppressible episodes of increased thromboxane formation can be detected during the early phase of acute ischemic stroke, and 3) this finding may provide a rationale for testing the efficacy and safety of this drug in this setting.

This article has been cited by other articles:

				G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF]

				L. Marquardt, A. Ruf, U. Mansmann, R. Winter, M. Schuler, F. Buggle, H. Mayer, and A. J. Grau Course of Platelet Activation Markers After Ischemic Stroke Stroke, November 1, 2002; 33(11): 2570 - 2574. [Abstract] [Full Text] [PDF]

				A. Bruno, J. P. McConnell, H. H. Mansbach, III, S. N. Cohen, G. E. Tietjen, and N. U. Bang Aspirin and Urinary 11-Dehydrothromboxane B2 in African American Stroke Patients Stroke, January 1, 2002; 33(1): 57 - 60. [Abstract] [Full Text] [PDF]

				N. M Smith, R. Pathansali, and P. M. Bath Platelets and stroke Vascular Medicine, August 1, 1999; 4(3): 165 - 172. [Abstract] [PDF]

				F. van Kooten, G. Ciabattoni, P. J. Koudstaal, D. W. J. Dippel, and C. Patrono Increased Platelet Activation in the Chronic Phase After Cerebral Ischemia and Intracerebral Hemorrhage Stroke, March 1, 1999; 30(3): 546 - 549. [Abstract] [Full Text] [PDF]

				M. T. Littleton-Kearney, P. D. Hurn, T. S. Kickler, and R. J. Traystman Incomplete global cerebral ischemia alters platelet biology in neonatal and adult sheep Am J Physiol Heart Circ Physiol, April 1, 1998; 274(4): H1293 - H1300. [Abstract] [Full Text] [PDF]

				S. C. Blackman, G. Dawson, K. Antonakis, and G. C. Le Breton The Identification and Characterization of Oligodendrocyte Thromboxane A2 Receptors J. Biol. Chem., January 2, 1998; 273(1): 475 - 483. [Abstract] [Full Text] [PDF]

				N. Delanty and C. J. Vaughan Vascular Effects of Statins in Stroke Stroke, November 1, 1997; 28(11): 2315 - 2320. [Abstract] [Full Text]

				F. van Kooten, G. Ciabattoni, C. Patrono, D. W. J. Dippel, and P. J. Koudstaal Platelet Activation and Lipid Peroxidation in Patients With Acute Ischemic Stroke Stroke, August 1, 1997; 28(8): 1557 - 1563. [Abstract] [Full Text]

				C. Morocutti, G. Amabile, F. Fattapposta, A. Nicolosi, S. Matteoli, M. Trappolini, G. Cataldo, G. Milanesi, M. Lavezzari, F. Pamparana, et al. Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation Stroke, May 1, 1997; 28(5): 1015 - 1021. [Abstract] [Full Text]

				W. M. Feinberg, L. P. Erickson, D. Bruck, and J. Kittelson Hemostatic Markers in Acute Ischemic Stroke: Association With Stroke Type, Severity, and Outcome Stroke, August 1, 1996; 27(8): 1296 - 1300. [Abstract] [Full Text]

				C. Patrono and G. J. Roth Aspirin in Ischemic Cerebrovascular Disease : How Strong Is the Case for a Different Dosing Regimen? Stroke, April 1, 1996; 27(4): 756 - 760. [Abstract] [Full Text]

				G. R. Thomas, H. Thibodeaux, C. J. Errett, M. M. Bednar, C. E. Gross, and W. F. Bennett Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis Stroke, June 1, 1995; 26(6): 1039 - 1046. [Abstract] [Full Text]

				J. H. Vial and C. Narkowicz Comparison of Cyclooxygenase Inhibition with Two Different Doses of Enteric Coated Aspirin in Normal Young and Elderly Subjects and Elderly with Cerebrovascular Disease Clinical and Applied Thrombosis/Hemostasis, January 1, 1995; 1(1): 55 - 61. [Abstract] [PDF]

				C. Patrono Aspirin as an Antiplatelet Drug N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294. [Full Text]